172 related articles for article (PubMed ID: 33283139)
1. Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study.
Pantano F; Manca P; Armento G; Zeppola T; Onorato A; Iuliani M; Simonetti S; Vincenzi B; Santini D; Mercadante S; Marchetti P; Cuomo A; Caraceni A; Mediati RD; Vellucci R; Mammucari M; Natoli S; Lazzari M; Dauri M; Adile C; Airoldi M; Azzarello G; Blasi L; Chiurazzi B; Degiovanni D; Fusco F; Guardamagna V; Liguori S; Palermo L; Mameli S; Masedu F; Mazzei T; Melotti RM; Menardo V; Miotti D; Moroso S; Pascoletti G; De Santis S; Orsetti R; Papa A; Ricci S; Scelzi E; Sofia M; Aielli F; Valle A; Tonini G
JCO Precis Oncol; 2020; 4():. PubMed ID: 33283139
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F
Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474
[TBL] [Abstract][Full Text] [Related]
3. Patients' Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study.
Mazzotta M; Filetti M; Piras M; Mercadante S; Marchetti P; Giusti R
Cancer Manag Res; 2022; 14():1237-1245. PubMed ID: 35356594
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study.
Mercadante S; Masedu F; Valenti M; Aielli F
J Clin Med; 2020 May; 9(5):. PubMed ID: 32375331
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study.
Mercadante S; Caraceni A; Cuomo A; Mammucari M; Marchetti P; Mediati RD; Natoli S; Tonini G
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1134-1139. PubMed ID: 36808361
[TBL] [Abstract][Full Text] [Related]
6. Multidimensional Statistical Technique for Interpreting the Spontaneous Breakthrough Cancer Pain Phenomenon. A Secondary Analysis from the IOPS-MS Study.
Cascella M; Crispo A; Esposito G; Forte CA; Coluccia S; Porciello G; Amore A; Bimonte S; Mercadante S; Caraceni A; Mammucari M; Marchetti P; Mediati RD; Natoli S; Tonini G; Cuomo A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439173
[TBL] [Abstract][Full Text] [Related]
7. A Longitudinal Study of Breakthrough Cancer Pain: An Extension of IOPS-MS Study.
Mercadante S; Caraceni A; Cuomo A; Mammucari M; Marchetti P; Mediati RD; Natoli S; Tonini G
J Clin Med; 2021 May; 10(11):. PubMed ID: 34073907
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
Mercadante S; Masedu F; Valenti M; Aielli F
Oral Oncol; 2019 Aug; 95():87-90. PubMed ID: 31345399
[TBL] [Abstract][Full Text] [Related]
9. Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain.
De Santis S; Simone MD; Mercadante S; Mediati RD; Vellucci R; Marchetti P; Tonini G; Cuomo A; Caraceni A; Natoli S; Armento G; Blasi L; Mammucari M;
Cancer Manag Res; 2021; 13():1747-1756. PubMed ID: 33642876
[TBL] [Abstract][Full Text] [Related]
10. Breakthrough cancer pain treatment in Spain: physicians' perception of current opioids utilization and prescription.
Villegas Estévez F; López Alarcón MD; Alonso Babarro A; Olay Gayoso L; de Castro J; Lería-Gelabert M; Melogno-Klinkas M
Curr Med Res Opin; 2020 Aug; 36(8):1383-1391. PubMed ID: 32453602
[No Abstract] [Full Text] [Related]
11. The Prevalence and Characteristics of Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.
Mercadante S; Maltoni M; Russo D; Adile C; Ferrera P; Rossi R; Rosati M; Casuccio A
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801478
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group.
Mercadante S; Marchetti P; Cuomo A; Mammucari M; Caraceni A;
Support Care Cancer; 2016 Feb; 24(2):961-968. PubMed ID: 26438145
[TBL] [Abstract][Full Text] [Related]
13. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
14. Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice.
Bossi P; Escobar Y; Pea F
Front Pain Res (Lausanne); 2022; 3():893530. PubMed ID: 35721659
[TBL] [Abstract][Full Text] [Related]
15. Current management of breakthrough cancer pain according to physicians from pain units in Spain.
Estévez FV; Alarcón MDL; Mayoral V; de Madariaga M; Margarit C; Duran JA; Martín-Arroyo JMT; Carregal A;
Clin Transl Oncol; 2019 Sep; 21(9):1168-1176. PubMed ID: 30783918
[TBL] [Abstract][Full Text] [Related]
16. Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study.
Katz NP; Gajria KL; Shillington AC; Stephenson JJ; Harshaw Q
Postgrad Med; 2017 Jan; 129(1):32-39. PubMed ID: 27846789
[TBL] [Abstract][Full Text] [Related]
17. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
18. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Masel EK; Landthaler R; Gneist M; Watzke HH
Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
[TBL] [Abstract][Full Text] [Related]
19. Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain.
Ferrer Albiach C; Villegas Estévez F; López Alarcón MD; de Madariaga M; Carregal A; Arranz J; Trinidad Martín-Arroyo JM; Jiménez López AJ; Sanz Yagüe A
J Pain Res; 2019; 12():2125-2135. PubMed ID: 31372030
[No Abstract] [Full Text] [Related]
20. Breakthrough cancer pain: twenty-five years of study.
Mercadante S; Portenoy RK
Pain; 2016 Dec; 157(12):2657-2663. PubMed ID: 27653423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
